Proteins that are modified by chemical conjugation require at least two separate purification processes. First the bulk protein is purified, and then after chemical conjugation, a second purification process is required to obtain the modified protein. In an effort to develop new enabling technologies to integrate bioprocessing and protein modification, we describe the use of disulfide-bridging conjugation to conduct PEGylation during protein refolding. Preliminary experiments using a PEG-mono-sulfone reagent with partially unfolded leptin and unfolded RNAse T1 indicated that the cysteine thiols underwent disulfide-bridging conjugation to give the PEGylated proteins. Interferon-β1b (IFN-β1b) was then expressed in E.coli as inclusion bodies and found to undergo disulfide bridging-conjugation during refolding. The PEG-IFNβ1b was isolated by ion-exchange chromatography and displayed in vitro biological activity.
Introduction
Proteins that are modified by chemical conjugation generally require at least two separate purification processes. The bulk protein must first be purified, and then after chemical conjugation, a second purification process is required to obtain the modified protein [1] .
There are many protein modifications that are conducted for a wide range of applications in industry, and consumer and healthcare [2] [3] [4] . A clinically proven protein modification used on a wide range of proteins is the covalent conjugation of poly(ethylene glycol) (PEG) to a protein. Protein PEGylation increases the circulation time of the modified protein and has improved the clinical efficacy for several proteins [5] [6] [7] while also decreasing the propensity for protein aggregation [8] [9] [10] [11] [12] . Therapeutic proteins must meet stringent specifications for purity and their manufacture is often by batch processes that are complex and expensive. To simplify manufacturing, there is much ongoing effort to develop new enabling technologies to create continuous bioprocessing strategies, especially for downstream processing [13] [14] [15] [16] , e.g. the integration of protein refolding from inclusion bodies (IBs) and purification steps [17] .
There are many advantages to using E. coli for the production of proteins [18] [19] [20] [21] [22] [23] [24] (e.g. rapid growth and high yield), especially for non-glycosylated proteins (antibody fragments, some cytokines, novel protein scaffolds) which continue to be developed. Although not universally true [25] , IBs can contain a high proportion of the target protein which is protected from proteolytic degradation [18, [26] [27] . IBs can also be readily separated during early downstream processing. Unfortunately protein refolding from IBs often involves extensive optimisation and bioprocessing, but continuing improvements in IB solubilisation are resulting in better recoveries of the correctly folded protein [28] . Of the many additives that have been examined during protein folding from IBs, unconjugated PEG has also been used to suppress aggregation [29] [30] [31] [32] .
There is the possibility that covalently modifying a protein with PEG during refolding could be used to increase refolding recovery. If PEGylation during refolding can be achieved, then two separate purification processes for the starting protein and again for the PEGylated protein would not be necessary. The PEG modification step would be incorporated into the refolding process and less additives would be necessary for successful refolding to occur.
Refolding of more hydrophobic proteins might be possible where the presence of the conjugated PEG would impart steric shielding effects to minimise protein-protein interactions leading to aggregation. The PEGylation reagent must undergo efficient conjugation at a specific amino acid residue on the target protein for PEGylation to be conducted prior to the bulk protein first being purified or during refolding,
We have developed hydrolytically stable, bis-alkylation PEGylation reagents 1 and 3 ( Figure 1A ) that undergo conjugation with two cysteine sulfur atoms, derived from a reduced disulfide bond, to give a three-carbon bridge linking the cysteine thiols. This type of PEGylation is known as disulfide bridging PEGylation ( Figure 1B ) [33] [34] [35] . PEG-bis-sulfone 1 first undergoes an elimination reaction in situ to generate the PEG-mono-sulfone 3 ( Figure   1A ) which then undergoes conjugation with the protein by a sequence of addition-elimination reactions. Such reactions are known to be able to give a thermodynamically stable product [36] . The PEG-mono-sulfone 3 can be isolated and used directly. The reagent is much more selective for cysteine thiols than amines (e.g. N-terminus, residues of lysine, histidine, arginine) at pH values less than 8.0. Due to the reaction mechanism of the conjugation, PEGreagent 3 ( Figure 1B ) is able to produce the most stable product thermodynamically. Hence it was hoped the refolding process could be made more efficient by the presence of PEG and by the nature of the conjugation reaction.
During refolding, disulfide bonds are usually formed by two thiol-disulfide exchange reactions with a redox reagent or another protein [37] [38] . Disulfide bond formation is thought to occur after conformational ordering and partial folding of the protein [37] [38] [39] [40] [41] [42] . Disulfide bond formation is thermodynamically coupled to the conformational folding of the protein [37] [38] [39] [40] [41] [42] . Known as oxidative refolding, optimisation is often empirical requiring the judicious use of redox buffers and quenching conditions of the redox couple. The use of PEG-monosulfone 3 avoids the need for oxidative refolding. Although attempts to integrate PEG modification during refolding or after partial protein unfolding have been described [34, [43] [44] [45] [46] [47] [48] , there remains a fundamental need to examine more efficient and site-specific PEGylation reagents that would assist in the protein folding process.
FIGURE 1
Intially refolding PEGylation studies were conducted using PEG-mono-sulfone 3 with two model proteins, leptin and RNase T1 to evaluate the feasibility of our approach. We then describe PEGylation the during the refolding of interferon-beta 1b (IFN-β1b) which is clinically registered to treat multiple sclerosis and considered a difficult protein to refold. The majority of the studies described here were conducted with PEG-mono-sulfone 3 that was derived from a 20 kDa PEG precursor (hence PEG 20 -mono-sulfone 3). IFN-β1b is produced from E. coli, however it is well known to be a hydrophobic protein [49] [50] [51] that can be difficult to refold from IBs [52] . IFN-β1b is a cytokine and is an example of an α-helical barrel protein, of which several are used clinically [53] . Several cytokines are also PEGylated and some are used as first line treatments for disease (e.g. PEGylated IFN-α2: Pegasys™ and PegIntron™; and PEGylated GCSF: Neulasta™ and Lonquex™). PEGylated interferon-beta 1a (IFN-β1a), which is a glycosylated variant of IFN-β, was registered for clinical used in the USA in 2014 [53] [54] [55] . Preliminary refolding PEGylation experiments using the same PEG 20 -mono-sulfone 3 (derived from 20 kDa PEG) were conducted with partially unfolded leptin, another α-helical barrel protein, and RNase T1. Although RNase T1 is not a cytokine, it has two disulfide bonds and is known to readily refold. Our hope was to determine whether any of the disulfide rebridged RNase could be obtained during folding.
Materials & Methods

Materials
Recombinant lyophilized human leptin was purchased from Peprotech EC Ltd (cat no: 300-27). RNase T1 (from aspergillus oryzae) was from Worthington Biochem (cat no: RT1S).
SDS-PAGE analyses were conducted using an XCell Surelock Mini-Cell, precast 4-12% NuPAGE Bis-Tris gels and MOPs and MES running buffer, with Novex Sharp protein markers (Invitrogen). Gels were stained using Coomassie-based InstantBlue stain (Expedeon) and Silver Express® (Invitrogen). HiTrap SP FF cation, Q FF anion exchange and PD10 protein desalting columns were supplied by GE Healthcare. PEG-bis-sulfone reagent 1 was supplied from PolyTherics Ltd and the reagent was treated (15 mg in 1 mL of 50 mM sodium phosphate buffer, pH 7.4) at ambient temperature overnight to give the PEG-mono-sulfone 3.
MicroBCA assay and Ellman's reagent were obtained from Thermo Scientific. UV measurements were obtained with a Hitachi U-2800A dual beam spectrometer and a Wallac 
Methods
Refolding PEGylation of RNase T1
RNase T1 (0.45 mg/mL in 2.8 M ammonium sulfate, Worthington) was denatured by buffer exchange using a PD10 column into denaturing buffer (50 mM sodium phosphate 6 M guanidine hydrochloride (GuHCl; pH 7.8) and then DTT was added to give a concentration of 50 mM. After incubation at ambient temperature for 30 min, the DTT was removed using a PD10 column into 100 mM Tris-HCl, pH 8.0 containing 1.9 M GuHCl and 0. 
Activity assay for PEGylated RNase T1
Substrate solution was prepared by dissolving 10 mg of yeast RNA in 1 mL of Tris buffer (50 mM Tris-HCl, 2 mM EDTA, pH 7.5) [56] . Methylene blue buffer was prepared in an amber bottle by dissolving 1 mg of methylene blue hydrate in 100 mL of prepared Tris buffer. The absorbance of the prepared buffer solution at 688 nm was then checked and adjusted to 0.5 ± 0.01 by the addition of further buffer. For the assay, 920 µL of methylene blue buffer was added to 80 µL of RNA substrate solution in 1.5 mL cuvettes. Cuvettes were then preincubated in the dark for 10 min at 25 ºC to enable RNA/methylene blue complex formation.
The reaction was then started by the addition of 10 µL volumes of different concentrations of RNase T1 (10, 5, 2.5 and 1.25 µg) and the PEGylated conjugate (10 µg). No RNase T1 was added to control cuvette. The change in absorbance at 688 nm was measured over 20 min by spectrophotometer.
PEGylation and partial refolding of leptin
Lyophilised leptin (Peprotech EC) was reconstituted in the reduction buffer (50 mM sodium 
Expression and solubilisation of IFN-β1b inclusion bodies
The plasmid harbouring the sequence for human IFN-β1b along with an eight-residue Nterminal histidine tag (Gene Oracle) was amplified by polymerase chain reaction (PCR) using 
PEGylation of IFN-β1b on refolding
For PEGylation, the supernatant was buffer exchanged using a PD10 column into a refolding buffer (50 mM sodium phosphate, pH 7.8 containing 20 mM EDTA, 6 M GuHCl and 1 mg mL of n-dodecyl β-D-maltoside (DDM)). This step also served to remove the excess DTT that was used to solubilise the IBs. The concentration of the target protein in the prepared IBs was estimated using a human serum IFN-β1b ELISA kit. The concentration of the solubilised IFN-β1b inclusion bodies were then adjusted to 0.3 mg/mL by the addition of further denaturing buffer. Refolding was then carried out by a two-step dilution by the addition of the refolding buffer initially to 4 M GuHCl, then to 2 M GuHCl. Each dilution step was followed by an incubation at 4 °C for 4 h. To the prepared IBs was added 1 molar equivalent of 20 kDa PEG-bis-sulfone 1 (PEG 20 -bis-sulfone 1), which had been pre-activated overnight at 37 °C in 50 mM sodium phosphate, pH 7.8 in order to generate the reactive mono-sulfone form of the reagent in situ (PEG-mono-sulfone 3). PEG 20 -IFN-β1b was then separated from other reaction components such as unreacted protein, unreacted PEG and multi-PEGylated species using ion exchange chromatography (IEC). The PEGylation reaction mixture was initially buffer exchange using a PD10 column into 50 mM sodium phosphate, pH 6.0 containing 0.1 mg/mL DDM. The buffer exchanged reaction mixture was then loaded onto the column (HiTrap SP FF) and the diPEG-IFN-β1b conjugate eluted from the column using 0.2 M NaCl while the mono-PEG-IFN-β1b conjugate was eluted using 0.26 M NaCl and any unreacted native IFNβ1b was eluted with 0.4 M NaCl. Purity estimations were made by running each of the fractions on a 4-12% Bis-Tris SDS-PAGE gel and the concentration of the PEGylated conjugate was determined by UV and microBCA assay.
Western blot analysis
Reaction mixtures were analysis by 4-12% Bis-Tris SDS-PAGE and transferred onto nitrocellulose membranes using a XCell II™ Blot Module CE Mark (Invitrogen) for 1 h at 30 V. The membrane was then blocked for 1 h at ambient temperature using PBS supplemented with 0.1% Tween-20 (PBS/T) with 5% w/v dried skimmed milk. Blots were incubated with rabbit anti-IFN-β primary antibody (1/1000 dilution) for 1 h at ambient temperature and then with anti-rabbit alkaline phosphate (AP) conjugated secondary antibody (1/5000 dilution) (both from Abcam) for another 1 h at ambient temperature. The target protein was then detected using Sigma BCIP ® /NBT tablets.
In vitro bioactivity of PEGylated and refolded IFN-β1b
The activity of the refolded and PEGylated was assessed by antiviral assay based on the in order to pellet the dye. The media was aspirated from each well using a multi-channel pipette and the dye was solubilised in 100 µL DMSO. Finally, the absorbance of each was read at 570 nm using a plate reader.
MALDI-TOF mass spectrometry
All samples were buffer exchanged into 10 mM ammonium bicarbonate, pH 8.0 using desalting spin columns prior to analysis. Mass analysis was carried out by matrix-assisted 
Tryptic digestion and MALDI-TOF mass spectrometry
Sequence grade modified trypsin (Promega) was solubilised in 50 mM acetic acid to a concentration of 0.2 mg/mL. To samples of both the native protein and the mono-PEG-IFNβ1b conjugate were added a 1:20 ratio of trypsin to protein and incubated at 37°C for approximately 16 hours. Samples were then analysed by MALDI-TOF mass spectrometry according to method outlined above.
Stability studies
Aliquots of samples in 50 mM sodium phosphate, pH 7.4 were stored up to 4 weeks at 37 °C.
Sample stability was then assessed by SDS-PAGE analysis using both Coomassie InstantBlue and barium iodide staining.
Results
Refolding PEGylation of RNase T1.
The This characteristic of PEG migration is maintained when PEG is conjugated to a protein.
Since the molecular weight of RNase T1 is 11 kDa, the band at approximately 50 kDa is consistent with that expected for PEG 20 
FIGURE 2
Partial refolding PEGylation of leptin.
Leptin is a α-helical barrel protein with one disulfide bond located between a helix and a flexible loop. Preliminary experiments [35] showed that leptin could be PEGylated with PEG 20 -bis-sulfone 1 in the presence of arginine, which was necessary to suppress leptin aggregation after disulfide reduction. Partial reduction of other cytokines (e.g. IFN-α2) with the cysteines located in or near a helix does not result in the aggregation that is observed with leptin [34] . This is presumably due the location of the disulfide cysteines in or close to the helices and to the greater hydrophobic interactions between the helices to help maintain the tertiary structure after disulfide reduction. For this current study we wanted to explore the use of PEG 20 -mono-sulfone 3 to determine whether this reagent would effectively undergo disulfide-bridging conjugation with partially unfolded leptin.
Disulfide reduced leptin was found to precipitate from solution in the absence of arginine with no formation of the PEG 20 -leptin conjugate ( Figure 3A, lane 4) . In the presence of 2 M arginine hydrochloride and using 1.5 eq. of PEG 20 -mono-sulfone 3, the desired PEG 20 -leptin product was formed in good conversion (~55%) ( Figure 3A , lanes 5-6). Trace amounts of higher molecular weight PEGylated products were also observed ( Figure 3A , lanes 5-6) using these conditions. No conjugation was observed when the PEG 20 -mono-sulfone 3 was added to leptin that had not been previously incubated with DTT ( Figure 3A Figure 3D ), which is consistent for the PEG fragment 12 ( Figure 3C ) derived from the 20 kDa PEG-mono-sulfone 3.
Expression of IFN-β1b and refolding PEGylation from inclusion bodies.
Expression of (IFN-β1b) was induced for 2. The total yield of PEG 20 -IFN-β1b (600 µg in IFN-β1b) following this single step of purification was ~12% as determined by UV and microBCA protein assay. This yield is considered to be very good when compared to the process flow of conventional purification of the bulk protein, modification and then purification of the modified protein.
No non-specific conjugation was observed in the presence of PEG 20 -mono-sulfone 3 when iodoacetamide had first been used to block the cysteine residues ( Figure 4B , lane 5).
When no PEG reagent was added to the refolding reaction, no refolded protein could be The activity of the PEG 20 -IFN-β1b conjugate was evaluated using an antiviral assay based on the ability of IFN-β1b to protect A549 cells from the effects of the encephalomyocarditis virus (EMCV) ( Figure 5A ). The PEG 20 -IFN-β1b conjugate was found to have an ED 50 value of 389 ± 32 pg/mL while the unmodified IFN-β1b (NIBSC standard)
had an ED 50 of 2 ± 0.1 IU/mL (n=4). A Daudi-based antiproliferative assay showed that the PEG 20 -IFN-β1b conjugate ( Figure 5B ) displayed an ED 50 value of 2688 ± 301 pg/mL and the unmodified IFN-β1b (NIBSC standard) displayed an ED 50 value of 292 ± 30 IU/mL (n=4).
FIGURE 5
4. Discussion
Refolding driven by disulfide bridging conjugation
Therapeutic proteins often have an accessible disulfide bond. Disulfides [40, 58] , especially accessible disulfides [59] , can act to increase the stability of the folded protein. The reaction mechanism for conjugation ( Figure 1B ) via an addition-elimination pathway provides the means to produce the thermodynamically most stable product [36] . This results in the conjugation of PEG via formation of a three-carbon bridge between the two cysteine thiols derived from a native disulfide [33] [34] [35] . The thermodynamic nature of the disulfide rebridging reaction is potentially valuable to help drive refolding without the need for redox couples during the refolding process while also simultaneously modifying the protein.
Introduction of the PEG-mono-sulfone 3 to the refolding solutions of RNase and IFN-β1b was conducted when these proteins were partially refolded. Although many competing reactions remain possible, our observations indicate that the disulfide bridging PEGylation was able to occur as the protein completed its refolding.
We have also shown previously with several examples that disulfide bridging conjugation yields biologically active protein and that the thiol ether bonds in the conjugate are more stable than the original disulfide [33] [34] [35] [60] [61] [62] . Secreted proteins that are prepared from different sources are also purified before chemical modification. We anticipate our reagents would also be useful to modify secreted proteins early in their initial purification process in an analogous way to the modification of proteins during refolding from inclusion bodies.
Other methods of conjugation generally, and PEGylation specifically, do not target the two cysteine thiols of a native disulfide bond. These other conjugation methods are not involved in the aspect of protein folding that is related to the formation of covalent bonds between amino acid residues. In the case of difficult-to-fold proteins such as IFN-β1b, we wanted to show that the concept of disulfide bridging conjugation could also be used to aid the folding process. The presence of PEG on the conjugation reagent would also be advantageous to drive refolding since it is known that PEG additives can be used during refolding to suppress aggregation [29] [30] [31] [32] and these favourable effects may be enhanced once PEG is site-specifically conjugated to the protein.
Reagent stability in refolding conditions
Dilution-based refolding was used in our studies because it is a simple and widely used method for small-scale refolding studies and has been scaled for use in protein manufacture.
Although we recognise that refolding processes vary widely with each protein, our intent was to establish if PEGylation could be accomplished during refolding without substantially modifying what would be considered to be typical refolding conditions. Therefore, denaturant (6 M GuHCl) was used in our refolding experiments in the presence of only a small stoichiometric excess of the PEGylation reagent 1 or 3 (typically 1-2 equivalents). In spite of the high levels of denaturant present in the refolding buffer, the hydrolytic stability and thiol selectivity of reagents 1 and 3 are important characteristics to allow refolding PEGylation to be possible. The use of a slight stoichiometric excess of the reagent is also an important criterion to consider the potential scalability of our strategy. Results also indicated that the efficiency of PEGylation was improved when the refolding conjugation reactions were conducted in the presence of an aggregation suppressant. While the refolding conjugation conditions can be further optimised, it was gratifying that (i) the reagent was not consumed in these conditions, (ii) that PEGylation was observed and (iii) the PEGylated protein could be purified, isolated and characterised.
Reagent thiol selectivity maintained in refolding conditions
Thiol selectivity for reagent 1 (and thus reagent 3) is well established [33-35, 60, 62-63] .
Characterisation of the refolding PEGylation of leptin with reagent 3 is consistent with
PEGylation on the leptin cysteine thiols (Figure 3 ). When the expressed IFN-β1b was pretreated with iodoacetamide to cap the cysteine thiols, no PEGylation was observed. RNase T1 is a protein with two disulfide bonds and we found that it was possible to tailor the reactions to favour the PEGylation of only one disulfide bond by adding the PEG later in the refolding process when the disulfide formation had already started. By fully unfolding the protein there is potential for both disulfide scrambling as well as the generation of multi-PEGylated species especially in the case of proteins containing multiple disulfide bonds. The use of small excesses of PEG such as those utilised here would also decrease the potential for any intermolecular crosslinking reactions that could occur between proteins and instead favor the formation of the proteins disulfide bridge. Typically PEGylation with reagent 1 is conducted on a fully folded protein after reduction of the accessible disulfide bond. Under these conditions the cysteine thiols remain spatially close. It is remarkable that a fully unfolded protein with more than one reduced disulfide bond can undergo disulfide bridging PEGylation. Using this method the desired conjugate could be isolated from the reaction mixture with good purity using only a single purification step.
Maintenance of biological activity
Some loss of biological activity is expected for PEGylation as a result of PEG shielding effects [7] , which causes a decrease in the rate of association during binding to the target ligand or receptor [60, 64] . For many proteins the existence of biological activity is a good indication of correct folding. Where the formation of the protein's disulfide bond is intrinsic to the biological activity, as in the case of RNase T1 and IFN-β1b, this can be used to further corroborate that PEG conjugation by disulfide rebridging has occurred. However, since
PEGylation was conducted during protein folding, it is possible that some misfolded modified protein was present.
Conclusion
In conclusion, there is a continued need to simplify the processes used to obtain protein therapeutics. The PEG-mono-sulfone 3 can be used during protein refolding to undergo disulfide rebridging conjugation. Many protein therapeutics require PEGylation, or other modification, to improve clinical efficacy. Conducting PEG modification with site specific reagents that can be used before the protein is purified while also driving refolding has the potential to be used to develop continuous, more efficient and cost-effective protein manufacturing processes. The refolded PEGylated proteins described in this study could be purified by ion exchange chromatography and retained biological activity. While refolding is very protein specific, the disulfide rebridging approach has the potential to be further developed for disulfide-containing therapeutic proteins.
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